A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer

NCT03694522 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

155

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric Cancer

Interventions

BIOLOGICAL: Bemarituzumab
DRUG: Placebo
DRUG: Modified FOLFOX6

Sponsor

Five Prime Therapeutics, Inc.

Collaborators

[object Object]